Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AUTOINJECTOR versus NORMIFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AUTOINJECTOR versus NORMIFLO.
ATROPINE (AUTOINJECTOR) vs NORMIFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists.
NORMIFLO is a selective alpha-1 adrenergic receptor antagonist that inhibits the binding of norepinephrine to alpha-1 receptors in the smooth muscle of the prostate and bladder neck, leading to relaxation of these muscles and improved urine flow.
2 to 4 mg intramuscularly (lateral thigh) or intravenously, repeated every 10-20 minutes if needed until muscarinic signs abate, maximum 3 doses.
Adults: 75 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (adults); prolonged to 6-12 hours in elderly or hepatic impairment.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~30-50% unchanged; hepatic metabolism: ~50%; fecal: minor.
Renal excretion of unchanged drug accounts for 65-75% of elimination; biliary/fecal excretion accounts for 20-30%, with the remainder as metabolites.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent